<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 288 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page287.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=288">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 288 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 288</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=288"><img src="../thumb/288.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.10                                                        2020-04 / 251
       reacts.incl. Stev.- Johns. syndr./tox.epiderm.necrolys., photosens.,   mnths-17 yrs.support.by adult well-control.study evid./pharmacoki-  least.14 days aft. last.posit.cult., pts.remain.persist.neutropen.may
       angioneurot.oed., psorias.exacerbat., hepatobil.dysfunct., bld.dys-  net.data & addit.data from prospect.stud.  warrant longer ther.pend.resolut.
       cras., musculoskelet. disords.  (S4) IV SOL.FOR INFUS, 37/20.2.2/0544, 0545  Oesophageal & oropharyngeal candidiasis: 50 mg dly.
       Warnings and special precautions: Imp.ren. funct., discont.in   707123-001: 50 mg/10 ml, sngl.vial, R3 200,91  Invasive Aspergillosis: 70 mg sngl load.dos.on day 1 foll.by 50 mg
       case of S&S indicat.of hepat. dysfunct & progress.skin rash, clear.  707124-001: 70 mg/10 ml, sngl.vial, R3 200,91  dly.thereaft. Durat.based on sev. of pts.underly.dis/recov.from immu-
       reduc.in pre-exist.liv.dis., not recomm.in childr.due to limit. data, use   Dosage: Slow IV infus.over 1 hr. Do not use any diluent.contain.dextr.  no-suppress. & clinic respons. Dly.dos.incr.to 70 mg may be consid.if
       not recomm.in chron./act.liv.dis., psorias.poss.exacerbat.  or mix/co-infuse with other meds.  no evid.of clinic.respons.& ther. well tol.
       Interactions: Clear.accelerat.by meds.which induc. metabol.  Adults: Empiric.ther: Load.dos: 70 mg as sngl.dos. on day 1, follow.by   Paed.pts: Dos.in childr.& adolesc.(3 mnths.-17 yrs of age) based
       eg.rifampic., clear.inhibit.by meds. inhibit.cytochrome P450   50 mg dly.thereaft. Durat.bas. on clinic. respons.cont.until neutropen.  on body surf.area (ref.to prod. lit.for calc.). All indicats: Sngl.70
                                                                     2
       eg.cimetid., inhibits CYP2D6 -mediat.metabol.eg.TCA’s/beta-block./   resolv. Treat pts. found to have fung.infect.min.x14 days contin. x7   mg/m  load.dos. (not exceed.act.dos.of 70 mg) admin.on day 1 fol-
       SSRI’s & MAOI type B, menstr.irregul.with OC’s,  days aft.neutropen.& sympts.resolv. If well tol. dly. dos.may be incr.  low. by 50 mg/m  dly.thereaft.(not exceed.act. dos. of 70 mg dly).
                                                                          2
       BIO-FLUCONAZOLE IV, Biotech [P/S]  to 70 mg if adeq.respons.not obt.  Indiv.treatm.durat.to each indicat. as describ.for each indicat.in
                                                                  adults. If 50 mg/m well tol.but not provid.adeq.clinic. response
                                     Invasive candidiasis: Load.dos.70 mg on day 1 foll.by 50 mg dly.
                                                                           2
       Fluconazole.                                               dly.dos.may be incr.to 70 mg/m  (not exceed. act.dos. of 70 mg)
                                                                                2
       Indications: Adults & childr:: Cryptococ. meningit. in ment.alert   thereaft. Durat.dictat.by clinic.& microbiolog.respon. Contin.for at   if adeq.respons.not obt.
       pts.without local. neurologic. signs & follow-up ther.aft. amphotericin   least.14 days aft. last.posit.cult., pts.remain.persist.neutropen.may   Contraindications: Sev.hepat.insuff., paeds.with any degree of
       B ther., maint.ther.to prev.cryptococ. dis.relapse in AIDS pts., system.   warrant longer ther.pend.resolut.  hepat.insuffic., safety & effic.in childr.&lt; 3 mnths.not est., paeds.with
       candidias., oropharyng. & oesophag. candidias., fung.infect. prophy-  Oesophageal & oropharyngeal candidiasis: 50 mg dly.  endocardit./ osteomyelit./meningit.due to Candida, init.ther.for invas.
       lax. in pts. receiv.chemo and/or radiother.  Invasive Aspergillosis: 70 mg sngl load.dos. on day 1 foll.by 50 mg   aspergillos.in paeds., pregn.& lactat.
       Adults: Ac/recurr.vag.candidiasis & as prophylax. to reduc.recurr.in-  dly.thereaft. Durat.based on sev.of pts.underly.dis/recov.from immu-
       cid., candidial balanitis, dermatomycos. incl. tinea pedis, tinea corporis,   no-suppress. & clinic respons. Dly.dos.incr.to 70 mg may be consid.  Side effects: Bld.disords.incl.anaem., hypokalem., fluid overload.,
                                                                  hypomagnesaem., anorex., electrol. imbal., hyperglycaem., hypocal-
       tinea cruris, tinea unguium (onychomycosis) & derm. candida infects.  if no evid.of clinic.respons.& ther. well tol.
       (S4) INFUS, 42/20.2.2/0683. 2 mg/ml.  Paeds: Dos. in childr.& adolesc.(3 mnths. - 17 yrs of age) based on   caem., metabol. acidos., psych.disords., CNS disords., ocul.icterus,
                                                                  vis. blurr., eyelid oed., incr.lacrimat, CV disords. incl. thrombophlebit.,
       714024-001: 100 ml, 1xbot., R55,41  body surf. area (ref.to prod.lit.for calc.). All indicats: Sngl.70 mg/
                                      2
       Dosage: Cont.ther.requir.multipl.dos.treatm.until lab. tests & clinic.  m  load. dos. (not exceed. act. dos. of 70 mg) admin. on day 1 follow.   thorac.& mediastin.disords., dyspn., nas.congest., pharyngolaryng.
                                                                  pain, tachypn., bronchosp., cough, dyspn.paroxysm. nocturn., hypox.,
                                          2
       paramet.indic.act.infect.subsid. Maint.ther.usually reqd.in AIDS pts.  by 50 mg/m  dly. thereaft. (not exceed. act. dos. of 70 mg dly). Indiv.
       with cryptococc. meningit/recurr.oropharyng.candidias. Infts. und.2   treatm.durat. to each indicat. as describ.for each indicat.in adults. If   rales, wheez., GI disords., elev. liv. values., cholestas., hepatomeg.,
                                                                  hyperbilirubinaem., jaund., hepat.funct.abnorm., hepatotox., liv.dis-
                                                         2
                                         2
       wks.to receiv.childr.dos.but only given once every 72 hrs. Infts.2-4   50 mg/m well tol.dly. dos.may be incr.to 70 mg/m  (not exceed. act.
       wks.to receiv.childr. dos.every 48 hrs. Max.adult dly.dos.of 400 mg   dos. of 70 mg) if adeq.respons.not obt.  ord., gamma-glutamyltransfer. incr., skin & subcutan.tiss.disords.incl.
       not to be exceed.in childr.   Contraindications: Sev.hepat.insuff., paeds.with any degree of   tox. epiderm. necrolys./Stev.-Johns.syndr., arthralg., back /extrem./
       Infusion may be infus.at max.rate of 200 mg/hr. with compat.admin.  hepat.insuffic., safety & effic.in childr.&lt; 3 mnths.not est., paeds.with   bone pain, musc.weakn., myalg., ren. fail., pyrex., chills, infus./inj-site
       fluid. Mix.with any other drugs not recomm.  endocardit./ osteomyelit./meningit.due to Candida, init.ther.for invas.  reacts., periph.oed., tendern., chest discomf./-pain, fac. oed., malaise,
       Cryptococ.meningit: Adults: 400 mg on 1st day, then 200-400 mg   aspergillos.in paeds., pregn.& lactat.  oed., poss.histamine-mediat. sympts. incl.facial swell./warmth sen-
       dly depend.on clinic.respon.but usual.8 wks.follow.amphotericin B   Side effects: Anaem., headache, loc.reacts., GI disords., skin re-  sat.& bronchosp., anaphylax.
       ther & 10 wks. with monother. Childr.over 4 wks: 6–12 mg/kg/   acts.incl.Stev.-Johns. syndr./ tox.epiderm.necrolys., dyspn., fev., pain,   Warnings and special precautions:. Std. monit. of tacrolimus
       day depend.on severit.        chills, poss. histamine-mediat.sympts.incl.facial swell./ warmth.   bld.conc.& approp.dos. adjustm. recomm.for pts rec.both ther, long.
       Maint.ther.to prevent.cryptococ.meningit. relapse in AIDS pts:   sensat.& brochosp., anaphylax., hepat. dysfunct., swell.& periph.  course of ther.pend.resolut.of neutropen.in pts remain persistent.neu-
                                                                                           2
       Adults: 100-200 mg dly.       oed., hypercalcaem., phlebit./thrombophlebit., arthralgia. Paed.also:   tropenic, consid.dly.dos.of 70mg Casfolred (Paeds: 70 mg/m  dly not
                          st
       System.candidias: Adults: Init. 400 mg on 1  day, then 200 mg dly.   tachycard., flush., hypotens.   exceed.act. dly.dos. of 70 mg) with concom.metabol.induc. efavirenz/
       Dos.may be incr.to 400 mg dly.depend.on clinic. respons. Childr.over   Warnings and special precautions:. Std. monit. of tacrolimus   nevirapine/rifampcin/dexamethas./ phenytoin/carbamazepine, mod.
       4 wks: 6–12 mg/kg/day depend.on severit.  bld.conc.& approp.dos. adjustm. recomm.for pts rec.both ther, long.  hepat.insuff., discont.in case of anaphylax., monit.pts. develop. ab-
       Oropharyngeal candidias: Adults: 50-100 mg once dly.x7-14   course of ther.pend.resolut.of neutropen.in pts remain persistent.  norm.LFTs for evid.of worsen.hepat.funct.& eval. risk-benef.of con-
       days/long.in sev. immunocompris. pts. To prev.relapse in AIDS   neutropenic, consid.dly.dos.of 70mg cancidas (Paeds: 70 mg/m   2  tin.ther., less comm. non-Candida yeasts & non-Aspergillus moulds
       pts.admin.150 mg once wkly. Childr.over 4 wks: Init.6 mg/kg on   dly not exceed.act. dly.dos. of 70 mg) with concom. metabol.induc.   poss.not covered as effic.not est., hist.of allerg.skin reacts., monit.
       1  day follow.by 3 mg/kg once dly. x2 wks.at least to low. likeli-  efavirenz/nevirapine/rifampcin/dexamethas./ phenytoin/carbamaz-  liv. enzym.closely with concom.cyclosporin, heredit. condit.such as
        st
       hood of relapse.              epine, mod.hepat.insuff., discontin.in case of anaphylax., monit.  fruct.intol./gluc.-galact. malabsorpt./sucrase-isomaltase insuffic.
       Oesophag.candidiasis: Adults: Init.200 mg on 1  day follow. by   pts. develop.abnorm.LFTs for evid.of worsen.hepat. funct. & eval.  Drug interactions: 12 hr.bld.conc.of tacrolimus reduc., elev.liv.
                             st
       100-200 mg dly.with dos.of upto 400 mg dly if no clinic.respons.aft.14   risk-benef.of contin.ther.  test val., incr.AUC with cyclosporine, conc.reduc.by drug clear.in-
       days. Treat for min.3 wks. & x2 wks.aft.sympt.resolv. Childr. over 4   Drug interactions: 12 hr.bld.conc.of tacrolimus reduc., elev.liv.test   duc.eg. rifampicin/efavirenz/nevirapine/phenytoin/dexamethasone
                 st
       wks: Init.6 mg/kg on 1  day follow.by 3 mg/kg once dly. with dos.  val., incr.AUC with cyclosporine, conc.reduc.by drug clear.induc.eg.   or carbamazep.
       of upto 12 mg/kg/ day accord.to pt.condit.& respons. Treat for min.3   efavirenz/nevirapine/phenytoin/dexamethasone or carbamazep.  CIPLA FLUCONAZOLE 50, 200, Cipla Medpro [P/S]
       wks. & x2 wks.aft.sympt.resolut.                           Fluconazole
       Fung.infect.prophylax.in pts.receiv.cytotox. chemo-/radiat.  CANDACIDE, Ranbaxy [P/S]  Indications: Adults & childr: Cryptococ. meningit. in ment.alert
       ther: Adults: 50-400 mg dly.bas. on risk profile. Commenc. ther.sev.  Nystatin.  pts.without local. neurologic. signs & follow-up ther.aft. ampho-
       days bef. anticipat. neutropen & contin.x7 days aft. neutrophil count   Indications: Candid.infects.of oral cavity  tericin B ther., maint.ther.to prev.cryptococ. dis.relapse in AIDS pts.,
                    3
       rises above 1000 cells per mm  Childr.over 4 wks: 3–12 mg/kg/day   (S2) SUSP, 31/20.1.7/0288. 100 000 U/ml.  oropharyng.& oesophag. candidias., system.candidias., fung.infect.
       depend.on extent & durat.of neutropen.  701100-001: 20 ml, R37,31  prophylax. in pts.receiv.chemo and/or radiother.
       Vag.candidiasis: Adults: 150 mg as sngl.dos.  701100-002: 30 ml, R55,97  (S4) CAPS, 38/20.2.2/0098, 0100
       Recurr.vag.candidias: Adults: 150 mg once mnthly. Indiv.durat.  Dosage: Retain in mouth for as long as poss.bef. swallow. Contin.  703634-001: 50 mg, 14, R149,58
       which range from 4-12 mnths.  at least 48 hrs.aft.sympt.disapp.  704116-001: 200 mg, 30, R580,03
       Candida balanitis: Adults: 150 mg as sngl.dos.  Infts., adults & childr: 1-2 ml 4xdly. Dos.may be incr. to 4-6 ml 4xdly.  Dosage: Dos.& durat.bas.on site of infect.& indiv. respons.to ther.
       Derm.infects.eg.tinea pedis, corporis, cruris and candida   for sev.infects.in adults & childr.  Cont.ther.until clinic.paramet.& lab. tests indic.act.infect.subsid.
       infects: Adults: 150 mg once wkly. x2-4 wks. but up to 6 wks.  Contraindications: Safety in pregn.& lactat.not est., syst.mycos.  Maint.ther.reqd.in AIDS pts.with cryptococc.meningit/recurr. oro-
       for tinea pedis.              Side effects: GI disturbs., skin reacts.incl.Stev. John. syndr.  pharyng. candidias.
       Tinea unguium: Adults: 150 mg once wkly.x3-12 mnths until nail   Special precautions: Discont.if irrit./sensitisat. develops.  Adults:
       completely replac.            CANSTAT, (Aspen Pharmacare: Consumer) Pharmacare [P/S]  Cryptococ.meningit: Adults: Init.400 mg on 1st day, then 200-
       Contraindications: Concom.cisapride, pregn. & lactat., multiple   400 mg dly depend.on clinic.respons. Durat.usual.8 wks follow.am-
       dos.ther.in ren.impairm., avoid concom.astemizole.  Nystatin  photericin B ther. & 10 wks.for monother. Maint to prevent.relapse
       Side effects: Ser.hepatotox.with fatalit., prurit., rashes, urticar.,   Indications: Prevent.of oral cavity Candida albicans infects.  in AIDS pts: 100-200 mg/day.
       angioed., dry skin, abnorm.odour, alopec., exfoliat.cutan.reacts.,   (S2) SUSP, D/20.1.7/171. 100 000 u/ml  System.candidias: 1st day 400 mg, then 200 mg dly. Dos.may
       hypersens.reacts. incl.anaphylax., bld.dyscras., hypercholesterol-  835056-007: 20 ml, R36,63  be incr.to 400 mg dly.depend.on clinic. respons.which also deter-
       aem., hypertriglyceridaem., hypokalaem., QT prolongat., torsades de   Dosage: Admin.4xdly.  min.durat.
       pointes, CNS effs.incl.seiz., fatig., rigors, GI disturbs., taste pervers.,   Infts: 1 -2 ml Childr.& adults: 1-2 ml, may be incr.to 4 -6 ml.
       thirst, polyruia, fem.sex.dysfunct., intermenst. bleed., menorrhag.,   Side effects: Diarrh., GI distress.  Oropharyngeal candidias: 50-100 mg dly.x7-14 days/long.in sev.
                                                                  immunocompris.pts. To prev. relapse in AIDS pts: 150 mg once wkly.
       leukorrh., abnorm. vis., hyperton.  CASFOLRED, Dr Reddy’s [P/S]  Oesophag.candidiasis: 200 mg on 1  day follow. by 100-200
                                                                                    st
       Special precautions: AIDS pts.more suscept.to cutan. reacts.,   Caspofungin acetate equiv.to caspofungin  mg dly. Dos.upto 400 mg once dly poss. if no clinical respons.aft.14
       monit.theophyll.conc., concom nevirapine, congenit.malformat.with   Indications: Adults: Empiric.ther.for presum. fung. infects. in fe-  days to low.dos. Treatm. durat.3 wks. & x2 wks.aft.sympt.resolov.
       admin.dur. pregn., excret.in breast milk, imp.ren.funct., fluid admin.   brile neutropen.pts., invas. Candidias. incl.candidaem., oesophag/  Fung.infect.prophylax.in cytotox.chemother. &/radiat.ther:
       in pts req.Na/fluid restrict., hepat./ren.& haematolog. funct.disturbs.  oropharyng. candidias. where IV ther.approp., invas. aspergillosis in   50-400 mg dly.depend.on risk profile. Init.treatm.sev.days bef.neu-
       partic.in pts.with ser. underly. dis. such as AIDS and malign.  pts refract.to/intol.of other ther. incl amphotericin B, lipid formulat.  tropen.expect. & contin.x7 days aft.neutrophil count rises above
       Warnings:  Monit.pts.develop.abnorm.liv.funct. for more seri-  of amphotericin B & itraconazole. Paed: Safety & effectiven.in pts.   1 000 cells/mm 3
       ous hepat.injur.              3 mnths-17 yrs.support.by adult well-control.study evid./pharmacoki-
       Drug interactions: Incr.plasma conc.of meds. metabol.by cyto-  net.data & addit.data from stud.  Children: Max.adult dly dos.of 400 mg should not be exceed.
                                                                  For infts und.2 wks.of age.use dos.specif. below but only ad-
       chrome P-450 system, warfar. anticoag. effs.incr., plasma conc.of   (S4) LYOPHIL.POWD.FOR CONC.FOR SOL.FOR INFUS,
       oral sulphonylureas/ phenytoin/zidovudine/midazolam/ triazolam/  50/20.2.2/0945, 0946  min.once every 72 hrs. Those aged betw.2-4 wks.give the
                                                                  dos.every 48 hrs.
       rifabutin/tacrolimus incr., theophyll. clear. decr., life threaten.card.  723774-001: 50 mg, 1x vial, R1 828,50
       arrhythm.with cisapride, signific.rise in cyclospor.conc., hydrochloro-  723777-001: 70 mg, 1x vial, R1 828,50  Children over 4 wks.of age:
                                                                  Cryptococc.meningit: 6-12 mg/kg/day depend. on sev.of infect.
       thiazide incr.fluconazole plasma conc., rifampicin reduc.fluconazole   Dosage: Slow IV infus.over 1 hr. Do not use any diluent.contain.dextr.
       plasma conc., nevirapine expos.incr.  or mix/co-infuse with other meds.  System.candidias: 6-12 mg/kg/day depend.on severity. Durat.bas.
                                                                  on clinic.&mycologic.respons.
                                                                                    st
       CANCIDAS, MSD [P/S]           Adults: Empiric.ther: Load.dos: 70 mg as sngl.dos. on day 1, follow.  Oropharyngeal candidias: 6 mg/kg on 1  day follow.by 3 mg/kg
       Caspofungin anhydrous equiv.to caspofungin acetate  by 50 mg dly.thereaft. Durat.bas. on clinic. respons.cont.until neutro-  once dly. x2 wks.at least to decr. relapse risk.
                                                                                  st
       Indications: Adults: Empiric.ther.for presum. fung.infects. in fe-  pen.resolv. Treat pts.found to have fung.infect.min.x14 days contin. x7   Oesophag.candidias: 6 mg/kg on 1  day follow. by 3 mg/kg once
       brile neutropen.pts., invas. Candidias. incl.candidaem., oesophag/  days aft.neutropen.& sympts.resolv. If well tol.dly. dos.may be incr.to   dly.incr.dos.upto 12 mg/kg/ day accord.to pt.respons. Treat durat.
       oropharyng. candidias. where IV ther.approp., invas. aspergillosis in   70 mg if adeq. respons. not obt.  min.3 wks.& x2 wks.aft.sympt.resolov.
       pts refract.to/intol.of other ther.incl amphotericin B, lipid formulat.of   Invasive candidiasis: Load.dos.70 mg on day 1 foll.by 50 mg dly.  Fung.infect.prophylax.in cytotox.chemother. &/radiat.ther:
       amphotericin B & itraconazole. Paed: Safety & effectiven.in pts.3   thereaft. Durat.dictat.by clinic.& microbiolog.respon. Contin.for at   3-12 mg/kg dly.depend.on extent & durat.of induc.neutropen.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page287.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page283.html">283</a>&nbsp;&nbsp;&nbsp;<a href="page284.html">284</a>&nbsp;&nbsp;&nbsp;<a href="page285.html">285</a>&nbsp;&nbsp;&nbsp;<a href="page286.html">286</a>&nbsp;&nbsp;&nbsp;<a href="page287.html">287</a>&nbsp;&nbsp;&nbsp;<a href="page288.html">288</a>&nbsp;&nbsp;&nbsp;<a href="page289.html">289</a>&nbsp;&nbsp;&nbsp;<a href="page290.html">290</a>&nbsp;&nbsp;&nbsp;<a href="page291.html">291</a>&nbsp;&nbsp;&nbsp;<a href="page292.html">292</a>&nbsp;&nbsp;&nbsp;<a href="page293.html">293</a>
             </td>
             <td width="35%"><a href="page289.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page289.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
